Innovative approaches to the treatment of anxiety and stress-related disorders (resolution of the Expert Council)
TL;DR
Experts conclude that the restrictions on the use of maritupirdine in patients with organic brain disorders and epilepsy are not sufficiently justified and the use of maritupirdine is appropriate for adjustment disorders of various aetiologies.
Abstract
Anxiety and stress-related disorders are characterized by high prevalence, comorbidity and resistance to existing treatments in a significant proportion of patients. Treatment for anxiety spectrum disorders includes an educational program, psychotherapy and the use of medication. The most effective forms of psychotherapy are cognitive behavioural therapy and various relaxation techniques; in recent years, psychological methods have often been used not only in face-to-face sessions but also online. First-line treatments for anxiety spectrum disorders include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). In some cases, patients with anxiety spectrum disorders do not respond to SSRIs and SNRIs, and many patients discontinue their medication due to adverse effects; therefore, the search for new drugs remains a priority. This article summarises the findings of the Expert Council meeting (April 2026) dedicated to maritupirdine (Aviandr®), a multi-target antagonist of serotonin, a 2 -adrenergic and H 1 -histamine receptors. Based on preclinical and clinical data, including studies on generalized anxiety disorder and post-COVID-19 adjustment disorder, the drug's anxiolytic, antidepressant and pro-cognitive effects, favourable safety profile and absence of withdrawal syndrome have been confirmed. A pro-cognitive effect of the drug has been observed, consistent with data on the blockade of 5-HT6 and 5-HT7 receptors. Experts conclude that the restrictions on the use of maritupirdine in patients with organic brain disorders and epilepsy are not sufficiently justified. Further research into maritupirdine in organic mental disorders, including cognitive impairment and dementia, is required. The use of maritupirdine is appropriate for adjustment disorders of various aetiologies. Maritupirdine's favourable tolerability and safety profile is a significant advantage in the treatment of patients with anxiety disorders and those with stress-related disorders.